SAB Biotherapeutics Inc

NASDAQ:SABS   4:00:00 PM EDT
1.05
-0.02 (-1.87%)
Earnings Announcements

Sab Biotherapeutics Provides Company Update For Q3 2022 Financial Results

Published: 11/15/2022 14:13 GMT
SAB Biotherapeutics Inc (SABS) - Sab Biotherapeutics Provides Company Update for Q3 2022 Financial Results.
Sab Biotherapeutics Inc - Qtrly Loss per Share $0.16.
Sab Biotherapeutics - Reaffirms Existing Cash Runway Will Be Enough to Fund Operating Expenses, Capex Requirements Through July 2023.
Revenue is expected to be $5.9 Million
Adjusted EPS is expected to be -$0.10

Next Quarter Revenue Guidance is expected to be $2.35 Million
Next Quarter EPS Guidance is expected to be -$0.15

More details on our Analysts Page.